Clinical Trial Update: An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia [Phase 1, Phase 2]

View source ↗

Summary

Adaptive open-label Phase 1/2 trial to determine the recommended Phase 2 dose of CCTx-001 and evaluate safety, tolerability, and clinical activity in relapsed o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CCTx-001

Snippet

Sponsor: Advesya SAS | Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING